Share Prices & Company Research

Market News

10 May 2019 | 09:11

Byotrol says regulatory delay to exacerbate losses, but expects revenues to meet expectations

Anti-microbial technology company Byotrol said it expected regulatory delays in the US to exacerbate losses, though revenue was expected in line amid a boost from the contribution with Medimark Scientific.

The company expected to generate consolidated full year revenues of around £4.2m, in line with market expectations and an earnings (EBITDA) loss in the region of £0.450m, increased by the delayed regulatory approval in the US and by higher marketing and research costs in the US.

Looking ahead, the company touted further synergies to be released from the combination with Medimark Scientific.

'The MSL and Byotrol teams are working together well and are uncovering many potential synergies across the Group. We will seek to release these benefits in the new financial year, as the earn-out proceeds towards its conclusion in March 2020,' the company said.

At 9:11am: (LON:BYOT) Byotrol PLC share price was 0p at 2.18p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.